Angiogenesis and antiangiogenic treatment in lung cancer

Targeted Oncology

Volumn 1, Issue 4, 2006, Pages 215-219

  Morere J F ^a,b   Brechot, J M ^a   Etessami, R ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

Angiogenesis; Bevacizumab; Non small cell lung cancer; Small cell lung cancer; Sorafenib; Sunitinib; Thalidomide; ZD6474

Indexed keywords

EID: 33750048429     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-006-0031-4     Document Type: Review

References (21)

1. Alberg AJ, Samet JM (2003) Epidemiology of lung cancer. Chest 123:215-495
2. Alberg AJ, Brock MV, Samet JM (2005) Epidemiology of lung cancer: looking to the future. J Clin Oncol 23:3175-3185
3. Sheperd FA (2005) A targeted approach to reducing lung cancer mortality. J Clin Oncol 23:3173-3174
4. Shiller J, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346(2):92-98
5. Hyde L, Hyde CL (1974) Clinical manifestations of lung cancer. Chest 65:299-306
6. Vaportciyan AA, Nesbitt JC, Lee JS et al (2000) Cancer of the lung. In: Holland JF, Frei E (eds) Cancer Medicine, 5th ed. BC Decker, London, pp 1227-1292
7. Meert A, Paesmans M, Martin B et al (2002) The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87(7):694-701
8. Bariety M, Delarue J, Paillas, J, Ruliere R (eds) (1967) Les carcinomes bronchiques primitifs. Masson, Paris
9. Ushijima C, Tsukamoto S, Yamazaki K et al (2001) High vascularity in the peripheral region of non-small cell lung cancer tissue in associated with tumor progression. Lung Cancer 34:233-241
10. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl Med 285:1182-1186
11. Brechot JM (2003) L'angiogénèse et son inhibition dans le traitement des cancers bronchiques. La lettre du Pneumologue 6:117-121
12. Morgensztern D, Govindan R (2006) Clinical trials or antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474. Expert Review of Anticancer Therapy 6(4):545-551
13. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191
14. Sandler A et al (2005) Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial E4599. Proc Am Soc Clin Oncol 23:2s (abstract LBA4)
15. Socinski MA, Novello S, Sanchez JM et al (2006) Efficacy and of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC) : preliminary results of a multicenter phase II trial. Proc Am Soc Clin Oncol 24:364s (abstract 7001)
16. Gatzemeier U, Blumenschein G, Fosella F et al (2006) Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. Proc Am Soc Clin Oncol 24:364s (abstract 7002)
17. Natale RB, Bodkin D, Govindan R et al (2006) ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. Proc Am Soc Clin Oncol 24:364s (abstract 7000)
18. Heymach JV, Johnson BE, Rowbottom J et al (2005) ZD6474 plus docetaxel in patients with previously treated NSCLC: results of a randomized, placebo controlled phase II trial. 11th World Conference on Lung Cancer, Barcelona, Lung Cancer 49(suppl2):S35 (abstract 0-100)
19. Pujol JL, Breton JL, Gervais R et al (2006) A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease SCLC patients after response to chemotherapy: an intergroup study FNCLCC cleo 04- IFCT 00-01. Proc Am Soc Clin Oncol 24:378s (abstract 7057)
20. Sandler A, Herbst R (2006) Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12(14):4421s-4425s
21. Lilenbaum R, Axerold R, Thomas S et al (2006) Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. Proc Am Soc Clin Oncol 24:369s (abstract 7022)